Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

FDA Approves RYZUMVI for Presbyopia; Viatris Seeks Commercial Partner

17 October 2026 · By · Wire by Fusion42

Published

17 October 2026

Topic

operational-macro

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at clinicaltrialvanguard.com →

◆ Verified

Fusion42 · 17 October 2026 · Fusion42 review

The FDA approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for treating presbyopia in adults, expanding its previous indication for pharmacologically-induced mydriasis. Viatris is currently seeking a commercial partner in the U.S. to market the product.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

The FDA’s green light for RYZUMVI opens a valuable US market you can now enter if you move fast on commercial deals. Partners are clearly needed, so start engaging sales channels or alliances this week.

◆ Coverage

1 source · 17 Oct 2026

◆ Related on Wire

◆ Topics

Medtechfda-approvalophthalmologypresbyopiacommercial-partnershipmedtech